Prior authorization, coverage limits, and affordability screening increasingly determine when CAR T or bispecifics are ...
Six peptides received narrow advisory support for potential 503A Bulks List inclusion, an atypical outcome given FDA staff recommendations against all seven under review. Legal compounding remains ...
Young adults with sarcoma face challenges that extend well beyond treatment, and closing gaps in research funding and specialty care could improve outcomes for this population and beyond, according to ...
Anosheh Afghahi, MD, discusses biomarker testing, trial matching technology, and community-academic partnerships to improve ...
A phase 2, randomized, double-blind trial (N=50) used oral semaglutide 3 mg/day then 7 mg/day, combining cue-reactivity testing with Timeline Follow-Back naturalistic drinking assessment and objective ...
EBV seroconversion confers markedly increased MS risk in large longitudinal military cohorts, supporting EBV as necessary but ...
Divergent product biology emerged: high-dose responses tracked with naïve/central-memory enrichment, whereas low-dose ...
The study, “Geographical Access to Preferred Pharmacies in Medicare Part D,” published in the July 2026 issue of The American Journal of Managed Care ® (AJMC ®), analyzed pr ...
A federal judge heard arguments over whether CMS unlawfully narrowed the Medicaid work requirement exemption for medically frail beneficiaries. Richard G. Stearns of the U.S. District Court for the ...
For this week’s Managed Care Cast episode, The American Journal of ManagedCare ® (AJMC ®) spoke with Anuraag R. Kansal, PhD, ...
Vitiligo's clinical course splits into segmental and non-segmental presentations, each carrying a distinct prognosis. Dr. Rosmarin explains how disease activity, not just extent, determines whether a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results